Aktis Oncology (NASDAQ:AKTS) Stock Price Crosses Above 50 Day Moving Average – Here’s What Happened

Shares of Aktis Oncology (NASDAQ:AKTS) crossed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $19.13 and traded as high as $19.73. Aktis Oncology shares last traded at $19.46, with a volume of 137,186 shares trading hands.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. William Blair assumed coverage on shares of Aktis Oncology in a report on Wednesday, April 29th. They set an “outperform” rating on the stock. Weiss Ratings downgraded shares of Aktis Oncology from a “sell (d+)” rating to a “sell (d)” rating in a report on Tuesday. Finally, HC Wainwright raised their price target on shares of Aktis Oncology from $33.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, June 2nd. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Aktis Oncology presently has a consensus rating of “Moderate Buy” and an average price target of $32.50.

Aktis Oncology Stock Performance

The firm’s 50-day moving average is $19.13.

Aktis Oncology (NASDAQ:AKTS) last posted its earnings results on Monday, March 30th. The technology company reported ($18.17) earnings per share for the quarter. The company had revenue of $1.87 million for the quarter. As a group, equities analysts expect that Aktis Oncology will post -1.62 earnings per share for the current fiscal year.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.